NEWS ER
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Bioscience (Nasdaq: INVO) reported record Q2 2024 financial results, showcasing significant growth. Key highlights include:
- Revenue soared 481% year-over-year to $1,836,597
- Clinic revenue increased 611% to $1,807,921
- Total revenue from all clinics, including consolidated and equity method, grew 201% to $2,141,229
- Adjusted EBITDA improved by $1.1 million to $(0.5) million
- Net loss remained stable at $(2.2) million
The company's acquisition strategy is driving growth, with fertility centers in Middleton, Atlanta, and Birmingham showing sequential revenue growth and collective profitability. INVO aims to reach breakeven with current operations and plans to resume acquisition and new INVO Center activities in 2025.
- Revenue soared 481% year-over-year to $1,836,597
- Clinic revenue increased 611% to $1,807,921
- Total revenue from all clinics, including consolidated and equity method, grew 201% to $2,141,229
- Adjusted EBITDA improved by $1.1 million to $(0.5) million
- Net loss remained stable at $(2.2) million
The company's acquisition strategy is driving growth, with fertility centers in Middleton, Atlanta, and Birmingham showing sequential revenue growth and collective profitability. INVO aims to reach breakeven with current operations and plans to resume acquisition and new INVO Center activities in 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow